Perimenopause Commonly Missed Diagnoses: What Doctors Mistake It For

Why Perimenopause Gets Missed So Often

Perimenopause produces more than 30 documented symptoms, most of which overlap with other common conditions. Cycles may still arrive monthly while a woman experiences cognitive fog, palpitations, joint pain, and mood instability. Clinicians who anchor on the absence of hot flashes or on a normal FSH frequently rule out hormonal transition too quickly. Research published in Menopause confirmed that symptom clusters in perimenopause are highly variable, making pattern recognition difficult without a detailed menstrual and symptom history.

The FSH Problem

A follicle-stimulating hormone (FSH) level above 25 IU/L on day 2 to 5 of the cycle is sometimes used as a diagnostic marker, but FSH fluctuates dramatically across the perimenopausal years. One blood draw can fall squarely in the premenopausal range even when ovarian function is declining. The Endocrine Society's clinical practice guidelines explicitly state that serial FSH measurements are more informative than a single value, and that clinical assessment remains the primary diagnostic tool.

Estradiol is equally unreliable in isolation. Early perimenopause can produce supraphysiologic estradiol spikes before the eventual decline, meaning a high estradiol result may reassure a clinician while the woman is already experiencing significant cycle irregularity and vasomotor symptoms.

What the Diagnostic Criteria Actually Require

The Stages of Reproductive Aging Workshop (STRAW+10) classification system defines early perimenopause (Stage -2) as cycles with a length variability of 7 or more days compared to the woman's usual cycle, and late perimenopause (Stage -1) as 60 or more days of amenorrhea. The STRAW+10 publication in Menopause is the standard framework used in academic menopause medicine. Most general practitioners are not using this staging system in daily practice, which contributes directly to delays in diagnosis.

Perimenopause Misdiagnosed as Depression

Depression is the single most common misdiagnosis given to perimenopausal women. This is understandable, given that low mood, anhedonia, fatigue, and sleep disruption are shared features of both conditions. The problem is one of directionality. In many cases, the mood disturbance is driven by estrogen fluctuation and sleep fragmentation from vasomotor symptoms, not by primary major depressive disorder (MDD).

What the Data Show

The Study of Women's Health Across the Nation (SWAN) followed 3,302 women across multiple sites over more than a decade. SWAN data published in JAMA Internal Medicine showed that perimenopausal women had 2.5 times the odds of a high CES-D depression score compared with premenopausal women, even after controlling for prior depressive history. This elevated risk is real, but it does not mean SSRIs are the correct first treatment for every case.

A separate 2022 analysis in Menopause found that among women whose depressive symptoms emerged for the first time during the menopause transition, menopausal hormone therapy (MHT) reduced depressive symptom scores significantly, while response to antidepressant monotherapy was substantially lower than in age-matched non-perimenopausal women. That gap in treatment response is clinically significant.

Clinical Differentiation

Several features tilt the picture toward perimenopause-driven mood dysregulation rather than primary MDD:

• Mood symptoms that track tightly with the menstrual cycle, worsening in the late luteal or perimenstrual window
• Concurrent vasomotor symptoms (hot flashes, night sweats) disrupting sleep architecture
• New onset after age 40 with no prior depressive history
• Partial or no response to two adequate antidepressant trials

When those features are present, a 12-week trial of low-dose estradiol (typically 0.05 mg transdermal patch) may be diagnostically and therapeutically informative before adding a second psychotropic agent.

Perimenopause Misdiagnosed as Thyroid Disease

Hypothyroidism and perimenopause share fatigue, weight gain, cognitive slowing, mood disturbance, and irregular menstruation. Hyperthyroidism or subclinical hyperthyroidism shares palpitations, heat intolerance, and sleep disruption. The co-occurrence is common. Autoimmune thyroid disease (Hashimoto thyroiditis) peaks in women aged 40 to 60, exactly overlapping with perimenopause.

When Thyroid Testing Is and Is Not Enough

A normal TSH does not exclude perimenopause, and perimenopause does not exclude thyroid disease. Both can coexist. A 2021 review in the Journal of Clinical Endocrinology and Metabolism highlighted that perimenopausal estrogen fluctuation can alter thyroid-binding globulin concentrations, which may influence total T4 interpretation. Free T4 and TSH together give a cleaner picture, but even a fully normal thyroid panel does not mean hormone transition should be dismissed.

Red Flags That Point Back to Perimenopause

A perimenopausal pattern should still be considered when:

• TSH is normal but hot flashes, night sweats, or cycle changes are present
• Palpitations worsen in the perimenstrual window
• Cognitive symptoms (word-finding difficulty, short-term memory lapses) began around age 42 to 50
• Levothyroxine replacement is optimized yet fatigue and brain fog persist

Perimenopause Misdiagnosed as an Anxiety Disorder

Generalized anxiety disorder (GAD) and panic disorder are both over-diagnosed in perimenopausal women. Perimenopause produces physiological anxiety through three mechanisms: vasomotor instability triggering sympathetic surges, sleep deprivation reducing GABAergic inhibition, and estrogen withdrawal destabilizing serotonergic tone.

Physiological Anxiety vs. Primary Anxiety Disorder

The distinction matters because a benzodiazepine or SSRI prescribed for GAD will not address the underlying hormonal driver. A 2023 randomized trial published in JAMA evaluated fezolinetant (a neurokinin 3 receptor antagonist) in 501 women with moderate to severe vasomotor symptoms. Fezolinetant 45 mg daily reduced hot flash frequency by 59% at week 12 (P<0.001 vs. Placebo), and secondary outcomes showed significant improvement in sleep and anxiety measures without any anxiolytic medication.

This matters diagnostically: if treating the vasomotor symptoms resolves the anxiety, the anxiety was secondary to perimenopause, not primary.

Panic Attacks and Palpitations

New-onset panic attacks after age 40 should trigger a hormonal evaluation. Estrogen modulates amygdala reactivity, and declining estrogen in perimenopause can lower the threshold for panic-like responses. Research in Psychoneuroendocrinology showed that women in late perimenopause had significantly higher amygdala activation on fMRI in response to emotional stimuli compared with premenopausal controls. These are biological changes, not character pathology.

Perimenopause Misdiagnosed as Adult ADHD

Cognitive complaints during perimenopause are among the most distressing and least addressed symptoms in clinical practice. Women report difficulty concentrating, word retrieval failures, and a subjective sense that their processing speed has slowed. These complaints map directly onto the DSM-5 criteria for adult ADHD, and the age of first symptom onset, typically 40 to 50, coincides with the perimenopausal window.

The Estrogen-Cognition Connection

Estrogen receptors are distributed throughout the prefrontal cortex and hippocampus. Estrogen promotes dopaminergic and cholinergic neurotransmission, both of which underpin working memory and attentional control. A 2018 study in Neurology found that women in the menopausal transition performed significantly worse on standardized memory and processing speed tasks compared with premenopausal women of the same age and education level, with performance improving after the transition in women who initiated MHT.

Why the ADHD Diagnosis Sticks

Neuropsychological testing during perimenopause may indeed show attention and executive function deficits consistent with ADHD criteria. Stimulant medications (amphetamine salts, methylphenidate) prescribed for that diagnosis can modestly improve dopaminergic tone but do not address the estrogen-deficiency mechanism. Women who are started on stimulants without hormonal evaluation often report partial benefit followed by plateau or worsening as estrogen levels continue to decline.

A useful clinical decision framework: when a woman aged 40 to 55 presents with new-onset cognitive complaints and no childhood history of attention difficulties, perimenopause should be ruled out before an ADHD diagnosis is assigned. This means documenting menstrual cycle changes, querying vasomotor symptoms (including night sweats that may not be volunteered), and considering a 3-month trial of low-dose MHT before initiating stimulant therapy.

Perimenopause Misdiagnosed as Chronic Insomnia Disorder

Sleep disruption is one of the most prevalent and under-addressed perimenopausal symptoms. Up to 60% of perimenopausal women report significant sleep disturbance, according to data from the SWAN Sleep Study. Nocturnal hot flashes fragment slow-wave sleep and suppress REM sleep, producing a clinical picture that meets criteria for chronic insomnia disorder.

The Misdiagnosis Pattern

Women receive cognitive behavioral therapy for insomnia (CBT-I) or hypnotic medications (zolpidem, eszopiclone, trazodone) without any evaluation of whether vasomotor symptoms are driving the arousal. CBT-I is effective for primary insomnia, but its effect size is considerably smaller when hot flashes are disrupting sleep architecture 8 to 15 times per night.

Correct Sequencing

The 2023 NAMS Menopause Practice Guidelines recommend treating vasomotor symptoms first in women with concurrent sleep disruption, on the basis that sleep quality improves substantially once nocturnal hot flashes are controlled. MHT reduces hot flash frequency and severity by approximately 75% compared with placebo in most randomized trials, producing downstream improvements in sleep architecture that hypnotics cannot replicate.

Perimenopause Misdiagnosed as Irritable Bowel Syndrome or Functional GI Disorder

GI symptoms during perimenopause are frequently overlooked as a hormonal manifestation. Estrogen and progesterone receptors are present throughout the GI tract. Fluctuating estrogen alters gut motility, visceral sensitivity, and the gut microbiome composition. Bloating, constipation, diarrhea, and nausea that worsen perimenstrually are often attributed to IBS rather than hormonal transition.

A 2020 review in Alimentary Pharmacology and Therapeutics documented that IBS symptom scores in women aged 40 to 55 correlated significantly with reproductive hormonal status, with scores worsening as FSH rose and estradiol declined. Women in this age group meeting Rome IV criteria for IBS should have a concurrent hormonal evaluation, particularly when GI symptoms began or worsened at the onset of cycle irregularity.

Laboratory Testing: What to Order and What to Avoid

Perimenopause is primarily a clinical diagnosis. Labs support and contextualize the picture; they do not replace history-taking. The following approach aligns with current endocrine society recommendations:

Recommended Panel

• FSH and estradiol: draw on cycle day 2 to 5 if the woman is still cycling. Repeat in 6 to 8 weeks before acting on a single result.
• TSH and free T4: to exclude concurrent thyroid dysfunction
• CBC and CMP: to exclude anemia and metabolic contributors to fatigue
• Fasting glucose and HbA1c: insulin resistance increases in perimenopause and can amplify fatigue and cognitive symptoms

Tests That Add Little Value

• Anti-Mullerian hormone (AMH): AMH is useful in fertility assessment and premature ovarian insufficiency workup, but its predictive value for menopausal transition timing in women over 40 is limited. A 2020 analysis in Human Reproduction found AMH below 0.2 ng/mL did not reliably distinguish late perimenopausal from early postmenopausal women on clinical symptoms.
• 24-hour urinary catecholamines: ordered occasionally when palpitations or hot flashes raise concern for pheochromocytoma. Appropriate when blood pressure is labile, but not as a routine first step.

Treatment Options After Correct Diagnosis

Once perimenopause is correctly identified, management follows a stepped approach based on symptom severity and individual risk profile.

Menopausal Hormone Therapy

For women with vasomotor symptoms and no contraindications, MHT remains the most effective treatment. The 2022 Menopause Society position statement states: "For women aged younger than 60 years or within 10 years of menopause onset and no contraindications, the benefit-risk ratio is favorable for treatment of bothersome vasomotor symptoms and prevention of bone loss."

Standard perimenopausal options include:

• Transdermal estradiol 0.05 mg/day patch plus micronized progesterone 200 mg for 12 days/month (for women with a uterus)
• Low-dose combined oral contraceptive (20 mcg ethinyl estradiol) for women who also need contraception, as ovulation can still occur in early perimenopause

Non-Hormonal Vasomotor Treatment

For women with hormone-sensitive cancer history or strong contraindications to estrogen, FDA-approved options now include:

• Fezolinetant (Veozah) 45 mg orally once daily: approved May 2023. The SKYLIGHT 1 trial (N=501) showed 59% reduction in hot flash frequency at 12 weeks FDA approval label.
• Paroxetine mesylate 7.5 mg (Brisdelle): the only FDA-approved SSRI specifically for vasomotor symptoms, at a sub-antidepressant dose.
• Venlafaxine 37.5 to 75 mg daily: off-label but supported by evidence in women with breast cancer history.

Low-Dose Oral Contraceptives in Perimenopause

Low-dose combined OCPs (20 mcg ethinyl estradiol formulations) are appropriate for healthy non-smoking perimenopausal women under 50 who require contraception. They suppress vasomotor symptoms, regulate cycles, and prevent unintended pregnancy, which remains possible until 12 months of continuous amenorrhea confirm menopause. The ACOG Practice Bulletin on Hormonal Contraception confirms that low-dose OCPs are not contraindicated in healthy, non-smoking perimenopausal women.

Getting the Right Diagnosis: A Practical Patient Guide

Women who suspect their symptoms are being misattributed to another condition can take concrete steps to improve diagnostic accuracy.

Keep a symptom and cycle diary for at least 8 weeks before a clinical appointment. Record cycle length, flow, hot flash frequency, sleep quality on a 1-to-10 scale, and mood rating each day. This creates the longitudinal pattern that a single office visit cannot capture.

Request FSH and estradiol on day 2 to 5 of a cycle, and ask for the result to be repeated at least once before a treatment decision is made. Ask specifically whether STRAW+10 staging has been applied to your symptom picture.

If you are being treated for depression, anxiety, insomnia, or ADHD that began after age 40 with no prior history, ask your prescriber to document whether a hormonal evaluation was completed before that diagnosis was assigned.

The North American Menopause Society's Menopause Practice guidelines state that: "Many symptoms of the menopause transition can be mistakenly attributed to other medical or psychiatric conditions, leading to delays in appropriate treatment." A second opinion from a certified menopause practitioner (NCMP) is reasonable when symptoms persist despite conventional treatment.